1. South Korea Stocks

  2. •

    Health technology

  3. •

    Biotechnology
BCWORLD PHARM. Co., Ltd.

BCWORLD PHARM. Co., Ltd.

KKRX:200780
2,860.00
KRW
-55.00
(-1.89%)
-48.18EPS
46.45BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4,547.55
5,443
4,044.42
4,459.95
4,905
5,351.29
4,988.41
5,518.75
6,012.71
7,048.81
7,353.42
7,334.51
8,158
7,988.53
Basic EPS, GAAP
499.22
570.63
617.82
632.47
789.63
487.6
-150.41
-152.89
-178.51
27.27
257.85
-434.55
-527
-251.18
Free Cash Flow per Basic Share
-422.79
-637.65
-1,608.96
-1,203.24
-1,130.13
-2,442.04
-892.6
-1,335.63
-1,881.95
43.09
805.6
160.23
169.19
-308.5
Dividend per Share
12.43
12.66
62.06
- -
62.69
68.87
75.1
74.69
82.7
82.78
53.13
53.21
58.41
- -
Book Value per Share
2,532.6
6,029.36
6,585.39
7,939.81
8,731.2
8,440.74
9,278.07
8,145.94
7,884.29
7,791.06
7,995.86
8,259.46
6,972.14
6,915.74
Tangible Book Value per Share
2,404.65
5,897.52
6,457.39
7,792.07
8,579.51
8,274.74
9,138.23
8,032.23
7,664.98
7,514.14
7,702.34
7,967.44
6,723.33
6,674.25
Basic Weighted Avg Shares
7
7
10
10
10
10
10
10
10
10
10
10
9
10
Sales/Revenue/Turnover
30,375
35,692
41,415
45,658
50,207
54,792
51,497
57,030
62,079
72,703
75,111
74,814
75,800
79,812
Operating Margin (%)
13.33
14.74
15.97
15.14
17.67
10.22
-4.15
-3.68
-2.51
2.56
8.47
2
2.63
5.64
Depreciation Expense
1,235
1,748
1,378
1,735
2,615
3,308
3,659
4,569
5,174
7,208
7,470
7,694
7,949
8,068
Net Income, GAAP
3,335
3,742
6,326
6,475
8,083
4,993
-1,553
-1,580
-1,843
281
2,634
-4,433
-4,897
-2,510
Effective Tax Rate (%)
0.71
18.98
- -
3.78
5.87
9.48
- -
- -
- -
- -
- -
- -
- -
188.06
Profit Margin (%)
10.98
10.48
15.28
14.18
16.1
9.11
-3.02
-2.77
-2.97
0.39
3.51
-5.92
-6.46
-3.14
Working Capital
12,081
39,896
19,460
22,668
21,528
9,829
-7,600
-13,096
-18,658
-40,597
-44,161
-41,307
-40,638
-37,758
LT Debt
1,922
1,855
1,100
8,201
15,886
37,002
34,754
32,698
43,819
21,325
11,995
14,438
14,568
15,893
Total Equity
25,921
61,710
67,401
73,876
81,460
86,613
85,971
83,568
79,647
77,520
79,869
76,010
72,502
72,358
Return on Invested Capital (%)
- -
8.58
- -
8.55
8.72
4.21
- -
- -
- -
- -
- -
- -
- -
-2.48
Return on Capital (%)
- -
8.86
- -
8.62
8.73
4.34
- -
- -
- -
- -
- -
- -
- -
-5.1
Return on Common Equity (%)
- -
8.54
9.8
9.17
10.42
5.96
-1.8
-1.86
-2.23
0.35
3.27
-5.6
-6.62
-3.47

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
73,580
72,597
71,439
LT Borrowings
14,125
14,000
15,333
LT Finance Leases
512
568
560
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
42,567
56,332
46,453

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
45,310
49,075
47,217
Cash, Cash Equivalents & STI
7,587
6,811
4,451
Accounts Receivable, Net
16,806
18,736
17,318
Inventories
19,433
21,306
23,447
Total Current Liabilities
86,649
89,713
84,975
Payables & Accruals
- -
- -
- -
ST Debt
73,580
72,597
71,439
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.89%
-2.76%
-4.62%
Free Cash Flow
167.75%
321.2%
-3.82%
Net Income, GAAP
33.95%
95.98%
10.47%
Sales/Revenue/Turnover
6.43%
6.04%
1.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16,303
19,460
17,524
21,527
74,814
2025
15,823
20,442
19,251
20,284
75,800
2026
19,835
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-152.07
-172.73
-97.52
14.54
-434.55
2025
-182.73
-73
-108.83
-105.83
-527
2026
32.57
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
53.21
2025
- -
- -
- -
- -
58.41
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Seong-Han Hong
Full Time Employees
288
Sector
Health technology
Industry
Biotechnology
Address
22 Geumto-ro 40beon-gil Yeoju-si GY South Korea
IPO Date
Dec 15, 2014
Website
bcwp.co.kr
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
BCWORLD PHARM. Co., Ltd. manufactures and distributes generic pharmaceuticals in South Korea, specializing in prescription drugs across multiple therapeutic areas including musculoskeletal system agents; digestive system treatments such as peptic ulcer medications; circulatory drugs for hypertension and hyperlipidemia; central nervous system therapies; adrenocorticosteroids; narcotic analgesics and cancer pain treatments including muscle relaxants, anesthesia, and pain relief drugs; erectile dysfunction treatments; wellbeing injections; diuretics; antitussive expectorants; vaginitis treatments; anti-tuberculosis antibiotics; anti-emetic and antiviral drugs; anti-malignant tumor agents; antifungal agents; antihistamines; antidotes; and antipyretic/analgesic/anti-inflammatory products. Founded in 1980 and headquartered at 22 Geumto-ro 40beon-gil, Sujeong-gu, Seongnam-si, South Korea, the company operates advanced manufacturing facilities compliant with PIC/s, US cGMP, and EU-GMP standards, supporting domestic contract manufacturing organization (CMO) services and exports through proprietary formulation technologies like immediate/controlled release, fast-dissolving delivery systems, and sustained-release microparticles. It serves healthcare providers and patients primarily in South Korea with global ambitions evidenced by technology transfers and licensing deals. Recent developments include signing a joint marketing agreement for Myeongmun Fentanyl Patch in 2024; exclusive domestic sales contracts for Perinject (iron deficiency treatment) with Huiwei Pharmaceutical (China) and Nucynta (narcotic analgesic) with Grunenthal GmbH (Germany); technology transfers for generic stafen (dyslipidemia) with JP Bio and Noltec (antiulcer) with Vaxcell-Bio; an exclusive supply agreement for Sialanar pediatric medicine with Proveca (UK) via BC World Healthcare; recertification as a Ministry of Health and Welfare innovative pharmaceutical company through 2027; a joint development deal for Hydrafill medical device with ReGelTec (USA) in 2023; and completion of its Pangyo headquarters alongside BCWP_IND approval in 2022.